News Conference News AHA 2013 AHA 2013: Mix of Positive, Negative Trials Help Guide Interventional Practice November 24, 2013
News Conference News AHA 2013 French Registry: FFR Safely Reclassifies Almost Half of Revascularization Patients Yael L. Maxwell November 20, 2013
News Conference News AHA 2013 Similar Long-term Benefits With Mitral Valve Repair, Replacement for Ischemic MR Yael L. Maxwell November 19, 2013
News Conference News AHA 2013 Endovascular Revascularization Benefits PAD Patients When Added to Exercise Therapy Yael L. Maxwell November 18, 2013
News Conference News AHA 2013 Varying Cell Therapy Techniques Demonstrate Safety, Mixed Efficacy at AHA 2013 November 17, 2013
News Conference News AHA 2013 Renal Stenting Fails to Improve Outcomes vs. Medical Therapy Alone in RAS Patients Jason Kahn November 17, 2013
News Conference News AHA 2012 AHA 2012: Multiple Studies Provide Clinical Guidance for Interventional Community Jason Kahn November 11, 2012
News Conference News AHA 2012 ASCERT: CABG More Cost-Effective Than PCI Over Long Term Jason Kahn November 05, 2012
Presentation AHA 2012 Results of Exenatide Myocardial Protection In REvascularization (EMPIRE) Study Presenter: Weon Kim November 04, 2012
News Conference News AHA 2012 EMPIRE: Exenatide Cardioprotective in STEMI Patients Receiving DES Jason Kahn November 04, 2012
News Conference News AHA 2012 TRILOGY ACS Substudy: No Relationship Between Platelet Reactivity, Outcomes November 04, 2012
News Conference News AHA 2012 FREEDOM: CABG Superior to PCI in Diabetic Patients with Multivessel Disease November 04, 2012
News Conference News AHA 2012 ARCTIC: Bedside Platelet Monitoring Fails to Help DES Patients Jason Kahn November 04, 2012
News Conference News AHA 2012 Pair of Studies Look at Cost Effectiveness of PCI in Different Populations Jason Kahn November 04, 2012
News Conference News Supervised Exercise Improves Walking Outcomes Better Than Stenting in PAD November 16, 2011
News Conference News ‘Judicious Use’ of DES in Low-Risk Patients Could Save Over $200 Million per Year November 16, 2011
News Conference News AIDA STEMI: No Advantage for Intracoronary vs. Intravenous Abciximab November 13, 2011